Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update (Q34441837)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

gastrointestinal neoplasm

1 reference

7 August 2019

stomach neoplasm

1 reference

7 August 2019

colorectal neoplasm

1 reference

7 August 2019

tumor biomarkers

1 reference

7 August 2019

medical guideline

1 reference

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Andrea Nicolini

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Marta Kalousová

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

M J Duffy

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

R Lamerz

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Haglund

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Sturgeon

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

0 references

publication date

27 August 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

International Journal of Cancer

5 references

21 March 2019

3 April 2019

19 June 2019

7 August 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

134

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2513-2522

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

4 references

Europe PubMed Central

21 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

19 June 2019

Europe PubMed Central

7 August 2019

on focus list of Wikimedia project

0 references

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

The development of regorafenib and its current and potential future role in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Bevacizumab in colorectal cancer: current and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Identification of Lynch syndrome among patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

A future for faecal haemoglobin measurements in the medical laboratory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Adjuvant therapy in primary GIST: state-of-the-art

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Targeted therapy for gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Lynch syndrome diagnostics: decision-making process for germ-line testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

A preclinical and clinical review of aflibercept for the management of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

TFAP2E-DKK4 and chemoresistance in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Colon cancer screening: which non-invasive filter tests?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Molecular tests for colorectal cancer screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

The GIST paradigm: lessons for other kinase-driven cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Colorectal cancer screening for average-risk North Americans: an economic evaluation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Surveillance after curative resection of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cost-effectiveness of colorectal cancer screening - an overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Clinical relevance of microsatellite instability in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Microsatellite instability in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Mismatch repair deficient colorectal cancer in the era of personalized treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Towards global consensus in the treatment of gastrointestinal stromal tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Serum tumour markers: how to order and interpret them

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Follow-up after curative resection of colorectal cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Screening for colorectal cancer using the faecal occult blood test, Hemoccult

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Recommendations for the management of GIST patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Systematic review of microsatellite instability and colorectal cancer prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Grading quality of evidence and strength of recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Follow-up of patients with curatively resected colorectal cancer: a practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Follow-up of colorectal cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

A comparison of fecal occult-blood tests for colorectal-cancer screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Principles and practice of mass screening for disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

CEA serum levels in non-neoplastic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

6 July 2018

Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Fecal occult blood testing when colonoscopy capacity is limited.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Decrease in mortality in Lynch syndrome families because of surveillance.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

EGFR antibodies in colorectal cancer: where do they belong?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

27 October 2018

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting Highlights and Bethesda Guidelines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Follow-Up of Patients with Colorectal Cancer A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28384

21 January 2018

Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4217376

9 December 2018

Cost-effectiveness of two follow-up strategies for curative resection of colorectal cancer: comparative study using a Markov model

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: A prospective validation study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparing fecal immunochemical tests: improved standardization is needed

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/23852704

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.28384

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23852704%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34441837&oldid=1500915691"